Home » Stocks » ITRM

Iterum Therapeutics PLC (ITRM)

Stock Price: $1.45 USD -0.13 (-8.23%)
Updated Jan 27, 2021 1:54 PM EST - Market open
Market Cap 77.55M
Revenue (ttm) n/a
Net Income (ttm) -64.46M
Shares Out 20.39M
EPS (ttm) -3.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $1.45
Previous Close $1.58
Change ($) -0.13
Change (%) -8.23%
Day's Open 1.40
Day's Range 1.34 - 1.53
Day's Volume 13,871,866
52-Week Range 0.46 - 4.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 --

GlobeNewsWire - 2 weeks ago

DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generati...

GlobeNewsWire - 1 month ago

--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities --

GlobeNewsWire - 1 month ago

Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020

GlobeNewsWire - 1 month ago

Bilayer tablet patent application could provide U.S. patent coverage for Iterum's commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent co...

InvestorPlace - 1 month ago

Iterum Therapeutics (ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. The post Iterum Therapeutics News: Why ITRM Stock Is Rocketing Hig...

GlobeNewsWire - 1 month ago

-- F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved - - - - Potential Approval Q3 2021 with Priority Review --

GlobeNewsWire - 2 months ago

NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020

GlobeNewsWire - 3 months ago

DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...

GlobeNewsWire - 3 months ago

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

GlobeNewsWire - 3 months ago

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

GlobeNewsWire - 3 months ago

--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical compan...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gen...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gen...

GlobeNewsWire - 4 months ago

DUBLIN, Ireland and CHICAGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland and CHICAGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...

GlobeNewsWire - 5 months ago

--Meeting with FDA Scheduled for end of Q3-- --Meeting with FDA Scheduled for end of Q3--

GlobeNewsWire - 6 months ago

DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...

GlobeNewsWire - 6 months ago

DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral anti...

GlobeNewsWire - 6 months ago

Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens

GlobeNewsWire - 7 months ago

DUBLIN, Ireland and CHICAGO, June 15, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug r...

GlobeNewsWire - 7 months ago

DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and ...

GlobeNewsWire - 7 months ago

Study did not meet its primary endpoint Study did not meet its primary endpoint

GlobeNewsWire - 8 months ago

--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors --

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...

GlobeNewsWire - 1 year ago

Topline results expected in Q1 2020 Topline results expected in Q1 2020

Zacks Investment Research - 1 year ago

Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem anti...

GlobeNewsWire - 1 year ago

Topline results expected in Q1 2020 Topline results expected in Q1 2020

Zacks Investment Research - 1 year ago

Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahea...

Zacks Investment Research - 1 year ago

Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and...

Zacks Investment Research - 1 year ago

Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -17.68% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for...

Zacks Investment Research - 1 year ago

Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Iterum Therapeutics.

About ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Industry
Biotechnology
IPO Date
May 25, 2018
CEO
Corey N. Fishman
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
ITRM
Full Company Profile

Financial Performance

In 2019, ITRM's revenue was $37,000, a decrease of -95.74% compared to the previous year's $869,000. Losses were -$103.13 million, 33.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ITRM stock is "Sell." The 12-month stock price forecast is 1.75, which is an increase of 20.69% from the latest price.

Price Target
$1.75
(20.69% upside)
Analyst Consensus: Sell